Pharmacokinetic Study of Extended Infusion Meropenem in Adult Cystic Fibrosis Patients
Status:
Terminated
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
Meropenem is an intravenous antibiotic commonly used to treat acute exacerbation of
respiratory infections in cystic fibrosis. The research study aims to determine if a
different method of infusing the drug over 3 hours or longer, instead of the traditional
half-hour will improve target attainment of drug concentrations and bactericidal activity. A
secondary aim is to assess if the pharmacokinetics of meropenem is different during active
infection compared to non-infective stage. Twelve patients admitted with acute respiratory
infection and who requires meropenem will be enrolled into the study. Meropenem blood
concentrations collected over 8 hours will be measured after half-hour and 3-hour infusions
on different days. A pharmacokinetic modelling and Monte Carlo simulation program will use
the data to assess and predict the optimal method of dosing. When patients return for a
follow-up clinic visit, a single dose of meropenem will be administered and blood
concentrations will be measured to determine the pharmacokinetics during non-infective stage.
Phase:
N/A
Details
Lead Sponsor:
St. Michael's Hospital, Toronto Unity Health Toronto
Collaborators:
Sunnybrook Health Sciences Centre University of Toronto